Sepsis remains a critical public health issue globally. Furthermore, the condition is highly heterogeneous, making a one-size-fits-all treatment strategy ineffective. A groundbreaking trial, ImmunoSep, has investigated whether a precision approach to Sepsis Immunotherapy can improve outcomes for critically ill patients. The results suggest a paradigm shift in managing the complex, dysregulated immune response seen in sepsis.
Understanding the Precision Approach
The ImmunoSep trial was a randomized, double-blind, double-dummy, placebo-controlled study conducted across six countries. Researchers designed the trial to test whether tailoring immunotherapy based on a patient’s specific immune status would be beneficial. They identified two main patient subgroups: those with macrophage activation-like syndrome (MALS) and patients with sepsis-induced immunoparalysis (SII). Consequently, the doctors used specific biomarkers to stratify the patients. For instance, high blood ferritin levels (above 4,420 ng/mL) identified MALS, indicating a hyperinflammatory state. On the contrary, SII patients had low ferritin and reduced expression of the HLA-DR receptor on monocytes. This level of precision is necessary because previous undirected trials have failed to find an effective adjunctive therapy.
Sepsis Immunotherapy: Targeted Treatment for Endotypes
The personalized treatment strategy involved giving different drugs based on the diagnosed immune endotype. Patients with the hyperinflammatory MALS endotype received anakinra, an immunosuppressive drug. Conversely, patients identified with SII received recombinant human interferon-gamma (rhIFNγ), which acts as an immunostimulatory agent. Notably, both agents are already licensed for other conditions, confirming the feasibility of this approach. The primary endpoint for the trial was an improvement in organ dysfunction, specifically a decrease of at least 1.4 points in the Sequential Organ Failure Assessment (SOFA) score by Day 9. Ultimately, 35.1% of patients in the precision immunotherapy group achieved this goal compared with only 17.9% in the placebo group (P=0.002). Moreover, the study demonstrated a quicker resolution of the underlying infection and successful reversal of immune dysfunction by Day 28 in the treatment arm.
Implications for Clinical Practice in India
The ImmunoSep trial provides robust, large-scale evidence supporting a biomarker-guided approach to treatment. While the trial successfully met its primary endpoint of improved organ function, the 28-day mortality rate did not show a statistically significant difference between the groups (43.5% versus 49.7%). Therefore, clinicians must view the improvement in the SOFA score as a critical surrogate marker of better outcomes, requiring further investigation. The success of this precision strategy, using available drugs, is a major step forward for Sepsis Immunotherapy. Future research will focus on replicating these findings and determining the long-term impact on survival across the full spectrum of sepsis patients.
Frequently Asked Questions
Q1: What was the primary finding of the ImmunoSep trial?
The ImmunoSep trial found that precision immunotherapy, when guided by a patient’s immune status, significantly improved organ dysfunction (measured by SOFA score decrease) by Day 9 compared to standard care plus placebo.
Q2: How was the personalized approach to Sepsis Immunotherapy guided?
The personalized approach was guided by biomarkers to classify patients into two immune endotypes: macrophage activation-like syndrome (MALS) or sepsis-induced immunoparalysis (SII). MALS patients received anakinra, and SII patients received recombinant human interferon-gamma.
Q3: Did the ImmunoSep trial show a difference in 28-day mortality?
No. While the primary endpoint of improved organ function was met, the trial did not show a statistically significant difference in the 28-day mortality rate between the precision immunotherapy group and the placebo group.
References
- Giamarellos-Bourboulis EJ et al. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA. 2025 Dec 08. doi: 10.1001/jama.2025.24175. PMID: 41359996.
- Giamarellos-Bourboulis EJ et al. Personalized Immunotherapy in Sepsis: A Multicentre and Multinational, Double-Blind, Double-Dummy, Randomized Clinical Trial (ImmunoSep) Protocol. BMJ Open. 2022 Dec 20. doi: 10.1136/bmjopen-2022-067251.
- Angus DC. Adding Precision Immunotherapy Improved Sepsis Outcomes. MedPage Today. 2025 Dec 08.